T he family of fibroblast growth factors (FGFs) encompasses 18 FGF receptor ligands and 7 distinct receptor proteins with a wide expression range. They have distinct roles in embryonic development, in adult organ homeostasis and vascular adaptation, and in a wide range of diseases. Genome-wide association studies in hypertensive populations have shown a potential role of molecules in the FGF pathway.
T he family of fibroblast growth factors (FGFs) encompasses 18 FGF receptor ligands and 7 distinct receptor proteins with a wide expression range. They have distinct roles in embryonic development, in adult organ homeostasis and vascular adaptation, and in a wide range of diseases. 1 Genome-wide association studies in hypertensive populations have shown a potential role of molecules in the FGF pathway. 2 Polymorphisms in the FGF5 locus were associated with blood pressure regulation and hypertension in large populations of European 3, 4 and Japanese ancestry. 5 Variations in the FGF1 locus correlated with familial hypertension and with the upregulation of FGF1 expression in kidneys. 6, 7 Also, genomic analysis revealed that a polymorphism in the FGFBP1 locus (FGFBP1 [FGF-binding protein 1]) was associated with familial hypertension, and hypertensive subjects showed increased expression of BP1 mRNA and protein in renal tissues. 8 Studies in hypertensive rats corroborated a contribution of the FGFBP1 genomic locus to glomerular damage and to hypertension. 9 Still, we lack information about mechanisms by which BP1 may control blood pressure and how it fits into the known paradigms of blood pressure control. 10 Secreted FGF-binding proteins (BPs) shuttle paracrine-acting FGFs from their extracellular matrix storage sites to their receptors and, thus, enhance their signaling. 11, 12 BP1 (originally named HBp17 13 and FGF-BP) is the best characterized of the 3 known members of the family 14 and interacts via its C terminus 15 with FGF1, 2, 7, 10, and 22 in a reversible, noncovalent manner. 13, [16] [17] [18] Depletion of endogenous BP1 reduced FGF2 release and blunted tumor growth and angiogenesis of human cancer cells 19 and resulted in distinct developmental defects during chick embryogenesis. 20 On the contrary, BP1 is upregulated in angioproliferative Kaposi sarcoma, 21 contributes to an angiogenic phenotype of cultured endothelial cells, 22 and controls angiogenesis and wound healing in adult mice. 23, 24 Here, we evaluate how the upregulation of BP1 may cause hypertension. For this, we used a transgenic mouse model with conditional BP1 gene expression under tetracycline control. 23 We found that induction of BP1 expression results in sustained 
Methods

Conditional Transgenic Animal Model
Animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee. Transgenic animals carrying a human BP1 cDNA under the control of a tetracycline response element (TRE-BP1) were described.
23
Statistical Methods and Data Analyses
Data analyses are described in the online-only Data Supplement. P values <0.05 were considered significant.
Further details and methods are available in the online-only Data Supplement.
Results
Conditional Expression of BP1 In Vivo
We had found that BP1 transgene expression results in embryonic lethality because of vascular leakage. 25 Thus, we established a conditional transgenic mouse model where BP1 transgene expression is repressed by tetracycline (OFF) and induced by switching animals to a regular diet (ON), 23 thus avoiding the negative impact of embryonic gene expression. In vivo regulation of conditional BP1 mRNA and protein expression in kidneys of transgenic animals was confirmed by quantitative RT-PCR (reverse transcription-polymerase chain reaction) and staining of formalin-fixed, paraffin-embedded kidneys from BP1 OFF and ON transgenic animals ( Figure 1A and 1B). Inducible BP1 mRNA and protein expression was also confirmed in heart and lung tissues by quantitative RT-PCR and by Western blot analysis that showed the BP1 protein migrating at the predicted mass of 34 kDa after induction of expression ( Figure S1 in the online-only Data Supplement). Overall, we found that BP1 mRNA was inducible by 3-to 5-fold.
BP1 Expression and Blood Pressure Control
To test the effect of conditional expression of BP1, mean arterial pressure (MAP) was monitored by telemetry in conscious transgenic mice. Under control conditions (BP1 OFF), there is a circadian rhythm of MAP that varied by 20 mm Hg between periods of activity (night time) and rest (day time). A sinus wave function described the day/night variation of the data (Figure 2A ). Analysis of a 10-day period before and after induction of the BP1 transgene in the same animals showed a rise of MAP during the activity phase by >30 mm Hg ( Figure 2C ) and an almost doubling of the MAP changes between activity and rest periods (Figure 2A ). This overall increase in MAP coincided with a significant decrease in the heart rate and a dampened amplitude of circadian regulation ( Figure 2B ). The increase of blood pressure occurred within 2 days of a switch to the tetracycline-free, regular diet in parallel with the induction of the BP1 transgene ( Figure 2C ). Switching nontransgenic littermates from tetracycline-containing diet to regular diet did not change MAP ( Figure 2C , circles versus triangles).
Role of AngII and ROS
The increase in MAP and decrease in heart rate after induction of BP1 expression ( Figure 2A and 2B) are reminiscent of an angiotensin-like vasopressor effect that can depend on ROS signaling. 26 To assess whether endogenous AngII receptor signaling and ROS contribute to BP1-mediated hypertension, mice were treated with the receptor antagonist Candesartan or the redox-cycling antioxidant nitroxide tempol. 27 Candesartan reduced basal MAP ( Figure 2D 
Induction of BP1, FGF Pathway Activation, and Vessel Contractility
To evaluate whether conditional BP1 expression sensitizes resistance vessels in vivo, cremaster arterioles were exposed in anesthetized mice and superfused locally with vasoconstrictor or vasodilator ligands. Representative intravital microscopic images of an arteriole at baseline, with AngII (constriction) or acetylcholine (dilation) superfusion is shown in Figure 3A .
There was a 20-fold sensitization of the AngII vasoconstrictor response after the induction of BP1 gene expression (EC 50 =230 nmol/L versus 12 nmol/L; Figure 3B ; P<0.0001 BP1 OFF versus ON). This sensitization was prevented by pretreatment of animals with the FGFR kinase inhibitor PD173074 23 ( Figure 3B , filled black versus red circles). Control animals (BP1 OFF) showed only a small and insignificant effect after the FGFR kinase inhibitor ( Figure 3B , open black versus red circles).
We inquired whether BP1 expression also could sensitize the cremaster arterioles to other vasoconstrictive stimuli. We had found previously that adrenergic receptor activation in resistance arterioles, unlike AngII, does not induce ROS generation and induces vasoconstriction that is not enhanced by oxidative stress. 28 Thus, we selected phenylephrine as a ligand that activates α1-adrenergic receptors. The extent of vasoconstriction by phenylephrine was similar to AngII (Figure 3B versus 3C; BP1 OFF). But, unlike AngII, BP1 expression did not sensitize vessels to phenylephrine ( Figure 3C ). Neither the EC 50 (2 µmol/L) nor the maximal effect of phenylephrine were different between the BP1 ON and OFF groups ( Figure 3C ). Positive immunoreactivity results in dark brown staining. Figure  S1 shows BP1 protein and mRNA expression in heart and lung tissues.
Thus, conditional expression of BP1 sensitizes arterioles to AngII in vivo. This sensitization is dependent on FGFR signaling.
BP1 Impacts Contractility of Renal Afferent Arterioles
Isolated vessels provide an approach for the analysis of vascular function that is not affected by systemic cardiovascular regulation in the intact animal. BP1 upregulation related to human hypertension was found in the kidneys that are key organs in systemic blood pressure regulation. Thus, we evaluated the impact of BP1 expression in isolated renal afferent arterioles that are the major renal resistance vessels. 29 Figure 4A shows the experimental set-up with a glomerulus and an afferent arteriole mounted onto a perfusion pipette. Addition of AngII to this preparation leads to a concentration-dependent 
Contribution of FGF2 to the Effect of BP1
Kidneys contain among the highest concentrations of FGF2 protein that is immobilized in the extracellular matrix 30 and can be released by BP1 as outlined in the introduction. To assess a contribution by FGF2, we investigated the efficacy of AngII and the crosstalk with BP1 in renal afferent arterioles from FGF2 −/− mice. FGF2 −/− mice had shown a reduced vascular tone and lower blood pressure. 31, 32 We confirmed by telemetric measurements that MAP in FGF2 −/− mice is reduced significantly by 15 mm Hg relative to wild-type mice ( Figure  S2A , open versus closed bar). Also, we found that the effect of exogenously administered AngII on MAP was reduced ( Figure S2A) . Consistent with the blood pressure effect, AngII failed to induce a contraction in renal afferent arterioles isolated from the FGF2 −/− mice ( Figure 4B and 4C, open red symbols). The blockade of AngII effects in vessels from wild-type mice by an FGFR kinase inhibitor ( Figure 4B , red open versus blue symbols) corroborates the crucial role of FGF signaling for AngII efficacy. It is noteworthy that vessels from FGF2 −/− mice still contracted in response to other ligands: The effect of norepinephrine was indistinguishable between FGF2 −/− and wild-type controls ( Figure 4D , black versus red symbols), indicating a selective cross talk between AngII and FGF signaling. Renal AT1R (AngII receptor 1) mRNA was not changed on induction of BP1 expression or in FGF2 −/− mice ( Figure S3 ). Because FGF2 and BP1 are extracellularly acting proteins, we added recombinant proteins to renal afferent arterioles from FGF2 −/− mice to assess whether this would rescue AngII vasoconstriction. Although FGF2 alone did not impact the AngII response most likely because of its capture by the extracellular matrix, the combination of FGF2 and BP1 restored a full contractile response of AngII ( Figure 4C ).
Gene Expression and Pathway Analysis
An unbiased gene expression analysis by cDNA array was undertaken in kidneys before and 2 days after induction of BP1, that is, after the initial rise in blood pressure ( Figure 2C ). Upstream regulators were identified using the Ingenuity platform and gene set enrichment analysis to detect expression patterns associated with signaling pathways.
The upstream regulator analysis ( Figure 5A ; complete list in Table S1 ) showed positive z scores >+1 and P values <10 −10 for the gene sets controlled by the transcriptional regulators tumor suppressor P53 (TP53), NRF2 (nuclear factor erythroid-derived 2-like 2 [NFE2L2]), and CREB1 (cAMP responsive element-binding protein 1). TP53 modulates cellular stress response genes, 33 NRF2 regulates antioxidant genes, and ChIPseq has shown an overlap of the target genes of NRF2 and of CREB1. 34 This analysis corroborates the contribution of ROS signaling after BP1 induction that was shown to contribute to the effect in functional studies with the antioxidant tempol 27 ( Figure 2E ). FGF2 was also identified as one of the upstream regulators. The loss of the AngII contractile response in renal afferent arterioles from FGF2 −/− mice ( Figure 4C ) and the inhibition of AngII-mediated vascular contractility by an FGFR kinase inhibitor ( Figures 3B and 4B ) support a regulatory role of FGF2. Negative z scores <−1 in the upstream regulator analysis were related to drugs that can inhibit effects of BP1 expression, that is, AT1R (losartan), MKK (U0126; PD98059), and PI3K (LY294002). Also, microRNA-16 was indicated as a significant (P<10 -6 ) upstream regulator with a negative z score <−2. MicroRNA-16 controls endothelial cell response to growth factors in vivo and, thus, provides a negative feedback loop for growth factor signaling. 35 The gene set enrichment analysis showed significantly impacted hallmark pathways that are exemplified in Figure 5B (complete list in Table S2 ). P53 was identified as a hallmark pathway that matches with the identification of P53 as an upstream regulator. The hypoxia hallmark pathway can be integrated with the NRF2 upstream regulator and TNF-α pathway signaling via NFkB matches with NFkB as an upstream regulator. Thus, evaluation of gene expression with different platforms provides complementary insights into the regulation of tissue homeostasis after BP1 induction.
Signal Transduction Proteins
We hypothesized that an analysis of changes in protein phosphorylation and formation of signaling complexes could provide additional insight into altered pathways in BP1 ON versus OFF mice. Thus, kidney proteins were extracted with mild detergent to Figure 5 . Signal transduction changes in kidneys after the induction of BP1. A, Gene expression data were subjected to an analysis for upstream regulators using the Ingenuity platform (Methods section in the online-only Data Supplement). z scores and P values (−log) are shown. Relevant data points are labeled (red symbols). A complete list (gray symbols) is provided in Table S1 . B, Hallmark pathways from a gene set enrichment analysis of the gene expression data (Methods section in the online-only Data Supplement). NES indicates normalized enrichment score; q, false discovery-adjusted P value. A complete list is provided in Table S2 . C, Detection of phospho-MKK4 or phospho-p38 or phospho-JNK by immunohistochemistry of kidneys from BP1 OFF and ON mice (total n=3). Bar=50 µm. Positive immunoreactivity results in dark brown staining. D, Phospho-p38 Western blot analysis of kidney extracts from BP1 OFF and ON animals after immunoprecipitation for phospho-p38. Total p38 protein is shown for comparison. maintain protein/protein interactions and protein complexes captured with an immobilized antiphosphotyrosine (pY) monoclonal antibody. As established previously, changes in signal complexes can, thus, be revealed if one of the protein partners in the complexes is tyrosine phosphorylated (pY). 36 Two-dimensional gel electrophoresis was used to separate the pY-containing protein complexes. Imaging analysis of Coomassie-stained gels quantitated distinct spots that were identified by mass spectrometry. 36 Four proteins that integrate into the known signaling pathway were covered by at least 8 distinct peptides ( Figure  S4; Figure 6 ). Two of these pY-complexed proteins identified were increased by ≈4-fold after BP1 induction and are known downstream effectors of the Rho family of small G-proteins 37 that regulate a multitude of cellular functions, PAK2 (p21 CDC42/RAC1-activated kinase 2) 38 and CIT/ STK21 (citron or RHO-interacting, serine/threonine kinase 21). 39 In earlier studies, Sundaresan et al 40 have reported that Ras-related small GTP-binding proteins such as RAC1 function as cellular regulators of ROS, an effect that was mimicked by exogenously added growth factors. A third protein, MKK4 (=MAP2K4) was found 3.6-fold upregulated in a pY complex after BP1 expression. MKK4 integrates mitogenic and stress signaling and targets the MAP kinases JNK and p38. A fourth protein, PTPN12 (protein tyrosine phosphatase, nonreceptor type 12) was found reduced by 2.8-fold after BP1 induction. In general, PTPs are thought to function as negative feedback controls of tyrosine kinase activities that can be inactivated by ROS signaling. 41 PTPN12 has been linked to altered oxidative stress and its loss to enhanced oncogenic signaling. 42 
Validation of Signaling Proteins
For an independent validation of the nodes of signaling uncovered in the above studies, we analyzed kidney tissues by immunohistochemical staining. Staining of parallel tissue sections for phosphoproteins in the MAP kinase pathway downstream of the FGF receptor 1 showed an increase in phospho-MKK4, phospho-p38, and phospho-JNK after BP1 expression ( Figure 5C ). For p38, the induction of phosphorylation was confirmed by Western blotting of protein extracts ( Figure 5D ). No differences in phospho-ERK (extracellular signal-regulated kinase) staining of kidneys were seen (not shown).
FGF and AngII Pathway Crosstalk in Cultured Human Cells
Cultured kidney cells (HEK293) were used to expand the above findings in an animal model to human cells. Combinations of increasing concentrations of FGF2 and AngII were studied for their induction of phosphorylation of MKK4 and the MAP kinases ERK, JNK, and p38. An increase in phospho-MKK4, phospho-JNK, and phospho-p38 was found in the costimulation with FGF2 and AngII ( Figure S5 ). In contrast, costimulation with FGF and AngII did not induce phospho-ERK. A parallel analysis in human endothelial and smooth muscle cells ( Figure S6 ) corroborates this analysis. After costimulation with FGF2 and AngII, phospho-p38 was induced in contrast to phospho-JNK and phospho-ERK.
Discussion
Activation of GPCRs (G-protein-coupled receptors) and receptor tyrosine kinases such as the FGFR initiate converging signaling cascades in cells to elicit a phenotypic response. Earlier studies in rat aortic smooth muscle cells showed an increase of AngII-stimulated Ca 2+ release after treatment with FGF2 and a blockade of the increase after inhibition of the MAP kinase pathway, suggesting a crosstalk that could be relevant for the initiation of hypertension. 43 Also, FGF2 was found to be essential for mediating AngII-induced cardiomyopathy that used the JNK and p38 MAP kinase pathways. 44 Moreover, endogenous FGF2 has been implicated in pulmonary hypertension 45 and cardiac hypertrophy, 46 conditions associated with increased vascular resistance.
Some mechanistic insight into the cross talk between pathways that control vascular tone and angiogenic signals emerged from inhibitors of VEGF (vascular endothelial growth factor)-driven tumor angiogenesis used to treat cancers. VEGF pathway activity is restricted to endothelial cells, and the major side effect of systemic therapy with VEGF pathway inhibitors is hypertension caused by the reduction of constitutive endothelial NO synthase. 47 FGFs also act on endothelial cells, and their effects overlap with VEGF. Indeed, intravascular administration of exogenous FGF1 or FGF2 lowers the blood pressure in experimental animals and can correct hypertension by preferential targeting of endothelial signaling attributable to this route of FGF administration. 48, 49 Because endogenous FGFs also act on vascular smooth muscle cells, the balance with their endothelial activity explains the apparent paradox that FGF2-deficient mice are hypotensive 31, 32 ( Figure S2 ) despite the hypotensive effect of intravenously administered FGF2. It is conceivable that the lower MAP observed after induction of BP1 in tempol-treated animals ( Figure 2E , gray versus black bar) is also because of a shift to the vasodilatory FGF signaling under inhibition of ROS by tempol. Interestingly, AngII also shows distinct activity on blood pressure that depends on the cell type stimulated. Typically, AngII will cause vasoconstriction and a rise in blood pressure (Figure 3; Figure S2 ). However, AngII reduced blood pressure in animals that only expressed endothelial AngII receptors because of the vasodilatory effects of the endothelial stimulus. 50 Here, we show that the predominant effect of FGF pathway activation by the induction of BP1 expression is to increase blood pressure by sensitizing resistance vessels to AngII (Figures 3 and 4) . This sensitization to AngII vasoconstriction was reversed by an FGFR kinase inhibitor, supporting the notion that increased BP1 expression activates the FGF pathway and thus increases vessel sensitivity for AngII. The increased baseline sensitivity of resistance vessels was reflected in increased blood pressure that is dependent on AngII receptor signaling as evidenced by the inhibitory effects of the receptor antagonist Candesartan ( Figure 2D ). We do not know whether other antihypertensives may also be effective.
When evaluating the GPCR/FGFR cross talk further, we found a qualitative difference between AngII and α-adrenoceptor sensitization of arteriolar contractility after FGF pathway activation ( Figure 3B versus 3C and Figure 4C versus 4D) . We propose that this difference is because of the distinct downstream effectors of these GPCRs. Previous studies showed that chronic AngII infusion increased vascular superoxide that enhanced the pressor response 26 and increased arteriole constriction by AngII but not by norepinephrine. 51 Thus, distinct intracellular effectors can modulate the crosstalk of FGFR and AngII.
Perspectives
The modulation of FGF signaling by BP1 can regulate vascular sensitivity to endogenous AngII and hence control steadystate blood pressure. Together with the finding of genomic polymorphisms of the human FGFBP1 gene resulting in increased expression of BP1 in tissues, our studies establish BP1 as a potential driver gene of hypertension.
